$ORKA

Oruka Therapeutics, Inc. (ORKA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 22, 2026, Oruka Therapeutics, Inc. entered into a letter agreement with Todd Edwards pursuant to which Mr. Edwards

Oruka Therapeutics Inc. (ORKA) shares have surged over 500% since September 2025, driven by positive clinical trial results for its drug candidates ORKA-001 and ORKA-002. The company announced several key developments, including trial progress, data releases, and a licensing agreement. ORKA's stock reached a 52-week high of $115.52 in August 2026. Investors are watching for upcoming data releases and trial initiations.

Goncalves Joana (Chief Medical Officer) sold 7,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $111.84 ($109.65–$112.56, $0.78M total) across 4 trades on 2026-08-17 under a Rule 10b5-1 trading plan.

Biotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.

Quinlan Paul T (General Counsel) sold 52,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $108.49 ($106.05–$111.14, $5.64M total) across 6 trades on 2026-08-14 under a Rule 10b5-1 trading plan.

Agarwal Arjun (Senior Vice President, Finance) sold 10,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $106.66 ($104.67–$108.46, $1.07M total) across 5 trades on 2026-08-13 under a Rule 10b5-1 trading plan.

Oruka Therapeutics (ORKA) reported Q2 2026 net loss of $41.21 million, up from $24.57 million a year earlier. The company said it had $1.1 billion in cash, cash equivalents and marketable securities as of June 30, 2026. Phase 2 EVERLAST-A 28-week data for ORKA-001 is expected end of Q3 2026, with 52-week data in Dec 2026.

Oruka Therapeutics reported a wider net loss for Q2, citing higher research and development costs. The company’s quarterly results reflect increased spending on R&D, which contributed to the deterioration in profitability. The update is relevant for investors tracking Oruka’s burn rate and funding needs.

Oruka Therapeutics reported Q2 2026 cash, cash equivalents and marketable securities of $1.1B as of June 30, 2026, and a net loss of $41.2M. R&D was $43.3M and G&A $6.9M, with $8.9M interest income. The company cited clinical updates for ORKA-001 and ORKA-002 and said funding should support a BLA filing for ORKA-001.

Oruka Therapeutics, Inc. (ORKA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 1